Related Experiment Video
Updated: May 30, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Strengthening Antisense Oligonucleotide-Mediated Anti-Tumor Immunity via Metal-Organic Framework Nanoparticles
Julia A Nowak1, Ezra Cho1, Meredith A Davis1
1Department of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.
Abstract:
Tumor overexpression of programmed death-ligand one (PD-L1) inhibits immune recognition. Existing monoclonal antibodies are fragile and penetrate tumors poorly, leading to variable outcomes. Antisense oligonucleotides (ASOs) can reduce PD-L1 expression, but require frequent high dosing due to rapid degradation, clearance, and poor uptake. To overcome this, we harnessed metal-organic frameworks (MOFs) to protect and deliver ASOs, reducing PD-L1 expression and elevating downstream immunity. With various PD-L1-specific ASOs loaded into NU-1000 MOFs, we sustain release up to 7 days, reduce PD-L1 expression across triple negative breast cancer and melanoma, and stimulate dendritic cells to amplify T cell proliferation. This dual tumor and immune cell modulation via MOF-mediated ASO delivery increases tumor caspase-3 expression and killing of human melanoma with patient tumor-infiltrating lymphocytes, and elongates in vivo survival. This research highlights a strategy to utilize ASOs without sequence modifications and with a reduced dosing frequency, enabling broadly applicable oncogene-targeting oligonucleotide delivery.
Insights
Metal-organic frameworks (MOFs) protect and deliver antisense oligonucleotides (ASOs) to reduce PD-L1 expression in tumors. This novel delivery system enhances anti-tumor immunity and improves survival, overcoming limitations of current treatments.
Area of Science:
- Biotechnology
- Nanotechnology
- Immunology
Background:
- Tumor programmed death-ligand one (PD-L1) overexpression hinders immune responses.
- Current antibody therapies for PD-L1 are limited by poor tumor penetration and fragility.
- Antisense oligonucleotides (ASOs) reduce PD-L1 but suffer from rapid degradation and poor delivery.
Purpose of the Study:
- To develop a novel delivery system for antisense oligonucleotides (ASOs) to target PD-L1.
- To overcome the limitations of ASO degradation, clearance, and poor tumor uptake.
- To enhance anti-tumor immunity and therapeutic outcomes through MOF-mediated ASO delivery.
Main Methods:
- Loading various PD-L1-specific ASOs into NU-1000 metal-organic frameworks (MOFs).
- Evaluating sustained release of ASOs from MOFs for up to 7 days.
- Assessing PD-L1 reduction in triple-negative breast cancer and melanoma models.
- Investigating immune cell stimulation, including dendritic cell activation and T cell proliferation.
- Measuring tumor apoptosis (caspase-3 expression) and in vivo survival.
Main Results:
- MOF encapsulation sustained ASO release for up to 7 days.
- Reduced PD-L1 expression was observed in triple-negative breast cancer and melanoma models.
- Dendritic cell stimulation and enhanced T cell proliferation were achieved.
- Increased tumor caspase-3 expression and improved in vivo survival were demonstrated.
- MOF-mediated ASO delivery effectively modulated both tumor cells and immune cells.
Conclusions:
- Metal-organic frameworks (MOFs) provide a robust platform for protecting and delivering antisense oligonucleotides (ASOs).
- This strategy enables sustained ASO release, reduces dosing frequency, and bypasses the need for sequence modifications.
- MOF-mediated ASO delivery offers a broadly applicable approach for targeting oncogenes and enhancing anti-tumor immunity.
More Related Videos
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy